Government-Owned Inventions; Availability for Licensing, 76372-76373 [2016-26390]
Download as PDF
<![CDATA[
76372
Federal Register / Vol. 81, No. 212 / Wednesday, November 2, 2016 / Notices
requirements are simultaneously
consolidated under 0925–0001 and the
changes to the collection here are
related. Clinical trials are complex and
challenging research activities.
Oversight systems and tools are critical
for the NIH to ensure participant safety,
data integrity, and accountability of the
use of public funds. The NIH has been
engaged in a multi-year effort to
examine how clinical trials are
supported and the level of oversight
needed. The collection of more
structured information in the PHS
applications and pre-award reporting
requirements as well as continued
monitoring and update during the postaward reporting requirements will
facilitate the NIH’s oversight of clinical
trials. In addition, some of the data
reported in the RPPR will ultimately be
accessible to investigators to update
certain sections of forms when
registering or reporting their trials with
ClinicalTrials.gov.
Frequency of response: Applicants
may submit applications for published
receipt dates. For NRSA awards,
fellowships are activated and trainees
appointed.
OMB approval is requested for 3
years. There are no costs to respondents
other than their time. The total
estimated annualized burden hours are
307,116.
ESTIMATED ANNUALIZED BURDEN HOURS
Number of
respondents
Information collection forms
Reporting:
PHS 416–7 ...............................................................................................
PHS 6031–1 .............................................................................................
PHS 568 ...................................................................................................
iEdison ......................................................................................................
PHS 2271 .................................................................................................
PHS 2590 .................................................................................................
RPPR—Core Data ....................................................................................
Biosketch (Part of RPPR) .........................................................................
Data Tables (Part of RPPR) .....................................................................
PHS Inclusion Enrollment Report (Part of RPPR) ...................................
PHS Clinical Trial Report/Form (Part of RPPR) .......................................
Trainee Diversity Report (Part of RPPR) .................................................
Publication Reporting ...............................................................................
PHS 3734 .................................................................................................
Final Progress Report ..............................................................................
SBIR/STTR Phase II Final Progress Report ............................................
Average
burden per
response
(in hours)
Number of
responses per
respondent
Total annual
burden
hours
12,580
1,778
11,180
5,697
22,035
243
32,098
2,544
758
2,544
8,264
480
32,341
479
11,125
1,330
1
1
1
1
1
1
1
1
1
1
1
1
3
1
1
1
30/60
20/60
5/60
15/60
15/60
15
8
2
4
1
1
15/60
5/60
30/60
1
1
6,290
593
932
1,424
5,509
3,645
256,784
5,088
3,032
2,544
8,264
120
8,085
240
11,125
1,330
Reporting Burden Total .....................................................................
Recordkeeping:
SBIR/STTR Life Cycle Certification ..........................................................
........................
........................
........................
306,741
1,500
1
15/60
375
Grand Total ................................................................................
........................
203,394
........................
307,116
Dated: October 22, 2016.
Lawrence A. Tabak,
Deputy Director, National Institutes of Health.
[FR Doc. 2016–26447 Filed 11–1–16; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
AGENCY:
National Institutes of Health,
HHS.
sradovich on DSK3GMQ082PROD with NOTICES
ACTION:
Notice.
The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S. in accordance with
35 U.S.C. 209 and 37 CFR part 404 to
achieve expeditious commercialization
of federally-funded research and
development. Foreign patent
SUMMARY:
VerDate Sep<11>2014
17:18 Nov 01, 2016
Jkt 241001
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
FOR FURTHER INFORMATION CONTACT:
Licensing information and copies of the
U.S. patent applications listed below
may be obtained by writing to the
indicated licensing contact at the
National Heart, Lung and Blood
Institute, Office of Technology Transfer
and Development, National Institutes of
Health, 31 Center Drive Room 4A29,
MSC2479, Bethesda, MD 20892–2479;
telephone: 301–402–5579. A signed
Confidential Disclosure Agreement may
be required to receive copies of the
patent applications.
SUPPLEMENTARY INFORMATION:
Technology descriptions follow.
Methods for Artificial Oocyte
Activation
Description of Technology
Available for licensing and
commercial development for both
PO 00000
Frm 00042
Fmt 4703
Sfmt 4703
human and veterinary uses is a method
of activating mammalian oocytes. These
methods include contacting a
mammalian oocyte of interest arrested at
metaphase II with an effective amount
of a Regulator of G-Protein Signaling
(RGS)2 inhibitor; and contacting the
mammalian oocyte of interest with an
effective amount of a G protein coupled
receptor activator. In general, RGS
proteins stimulate the hydrolysis of GTP
bound to activated Ga subunits, leading
to signal termination. RGS2, which
inhibits both G-aq and G-as signaling
suppresses Ca2+ release in mature
mammalian eggs. Regulators of GProtein Signaling (RGS)2 inhibitor and a
G protein coupled receptor activator can
be used to artificially activate a
mammalian oocyte such that it re-enters
the cell cycle. Examples of RGS2
inhibitors can be nucleic acids like
siRNAs or dsRNAs. G-protein coupled
receptor activators can be acetylcholine,
a neurotransmitter such as serotonin,
hormones, natural or synthetic G
E:\FR\FM\02NON1.SGM
02NON1
Federal Register / Vol. 81, No. 212 / Wednesday, November 2, 2016 / Notices
protein coupled receptor ligands or
modulator, and acidic pH. The oocyte
can be fertilized in vitro to form an
embryo, which can be implanted in a
subject and developed to term or can be
used for the preparation of stem cells.
Potential Commercial Applications
• in vitro fertilization
Development Stage
• Early Stage
Inventors: Miranda L. Bernhardt,
Carmen J. Williams, Andres Gambini
(all of NIEHS), and Lisa M. Mehlmann
(University of Connecticut).
Intellectual Property: HHS Reference
No. E–253–2016/0.
• U.S. Provisional Patent Application
No. 62/405,803 filed 7 October 2016.
Licensing Contact: Michael
Shmilovich, Esq, CLP; 301–435–5019;
shmilovm@mail.nih.gov.
Dated: October 24, 2016.
Michael Shmilovich,
National Heart, Lung and Blood Institute,
Office of Technology Transfer and
Development, National Institutes of Health.
[FR Doc. 2016–26390 Filed 11–1–16; 8:45 am]
National Institutes of Health
National Cancer Institute; Notice of
Meeting
Pursuant to section 10(a) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the meeting of the
President’s Cancer Panel.
The meeting will be open to the
public, with attendance limited to space
available. Individuals who plan to
attend and need special assistance, such
as sign language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting.
sradovich on DSK3GMQ082PROD with NOTICES
[FR Doc. 2016–26389 Filed 11–1–16; 8:45 am]
Name of Committee: President’s Cancer
Panel.
Date: December 9, 2016.
Time: 9:00 a.m. to 4:00 p.m.
Agenda: Emerging Opportunities to
Streamline Cancer Drug Development.
Place: The Ritz Carlton Pentagon City,
1250 S. Hayes Street, Arlington, VA 22202.
Contact Person: Abby B. Sandler, Ph.D.,
Executive Secretary, President’s Cancer
Panel, Special Assistant to the Director,
Center for Cancer Research, National Cancer
Institute, NIH, 9000 Rockville Pike, Building
31, Room B2B37, MSC 2590, Bethesda, MD
20892–8349, 301–451–9399, sandlera@
mail.nih.gov.
Any interested person may file written
comments with the committee by forwarding
Jkt 241001
Date: November 29, 2016.
Time: 12:30 p.m. to 5:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Liying Guo, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4016F,
Bethesda, MD 20892, 301–435–0908, lguo@
mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: October 28, 2016.
Anna Snouffer,
Deputy Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 2016–26450 Filed 11–1–16; 8:45 am]
BILLING CODE 4140–01–P
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel, Member
Conflict: Topics in Cell Biology.
Date: November 29, 2016.
Time: 12:15 p.m. to 2:15 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Telephone Conference Call).
Contact Person: Janet M Larkin, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 1102,
MSC 7840, Bethesda, MD 20892, 301–806–
2765, larkinja@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Allergy, Autoimmunity,
Transplantation, and Tumor Immunology.
PO 00000
Frm 00043
Fmt 4703
Sfmt 4703
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
17:18 Nov 01, 2016
Dated: October 26, 2016.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory
Committee Policy.
National Institutes of Health
BILLING CODE 4140–01–P
VerDate Sep<11>2014
the statement to the Contact Person listed on
this notice. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
Information is also available on the
Institute’s/Center’s home page: https://
prescancerpanel.cancer.gov/, where an
agenda and any additional information for
the meeting will be posted when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS)
76373
Center for Scientific Review; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel, Member
Conflicts—Molecular and Cellular
Neuroscience.
Date: November 17, 2016.
Time: 1:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Telephone Conference Call).
Contact Person: Brian H Scott, Ph.D.,
Scientific Review Officer, National Institutes
of Health, Center for Scientific Review, 6701
Rockledge Drive, Bethesda, MD 20892, 301–
435–1730, brianscott@mail.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Program
Projects: Mechanisms of Cell Division.
Date: November 28, 2016.
E:\FR\FM\02NON1.SGM
02NON1
]]>Agencies
[Federal Register Volume 81, Number 212 (Wednesday, November 2, 2016)]
[Notices]
[Pages 76372-76373]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-26390]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The inventions listed below are owned by an agency of the U.S.
Government and are available for licensing in the U.S. in accordance
with 35 U.S.C. 209 and 37 CFR part 404 to achieve expeditious
commercialization of federally-funded research and development. Foreign
patent applications are filed on selected inventions to extend market
coverage for companies and may also be available for licensing.
FOR FURTHER INFORMATION CONTACT: Licensing information and copies of
the U.S. patent applications listed below may be obtained by writing to
the indicated licensing contact at the National Heart, Lung and Blood
Institute, Office of Technology Transfer and Development, National
Institutes of Health, 31 Center Drive Room 4A29, MSC2479, Bethesda, MD
20892-2479; telephone: 301-402-5579. A signed Confidential Disclosure
Agreement may be required to receive copies of the patent applications.
SUPPLEMENTARY INFORMATION: Technology descriptions follow.
Methods for Artificial Oocyte Activation
Description of Technology
Available for licensing and commercial development for both human
and veterinary uses is a method of activating mammalian oocytes. These
methods include contacting a mammalian oocyte of interest arrested at
metaphase II with an effective amount of a Regulator of G-Protein
Signaling (RGS)2 inhibitor; and contacting the mammalian oocyte of
interest with an effective amount of a G protein coupled receptor
activator. In general, RGS proteins stimulate the hydrolysis of GTP
bound to activated G[alpha] subunits, leading to signal termination.
RGS2, which inhibits both G-[alpha]q and G-[alpha]s signaling
suppresses Ca2+ release in mature mammalian eggs. Regulators of G-
Protein Signaling (RGS)2 inhibitor and a G protein coupled receptor
activator can be used to artificially activate a mammalian oocyte such
that it re-enters the cell cycle. Examples of RGS2 inhibitors can be
nucleic acids like siRNAs or dsRNAs. G-protein coupled receptor
activators can be acetylcholine, a neurotransmitter such as serotonin,
hormones, natural or synthetic G
[[Page 76373]]
protein coupled receptor ligands or modulator, and acidic pH. The
oocyte can be fertilized in vitro to form an embryo, which can be
implanted in a subject and developed to term or can be used for the
preparation of stem cells.
Potential Commercial Applications
in vitro fertilization
Development Stage
Early Stage
Inventors: Miranda L. Bernhardt, Carmen J. Williams, Andres Gambini
(all of NIEHS), and Lisa M. Mehlmann (University of Connecticut).
Intellectual Property: HHS Reference No. E-253-2016/0.
U.S. Provisional Patent Application No. 62/405,803 filed 7
October 2016.
Licensing Contact: Michael Shmilovich, Esq, CLP; 301-435-5019;
shmilovm@mail.nih.gov.
Dated: October 24, 2016.
Michael Shmilovich,
National Heart, Lung and Blood Institute, Office of Technology Transfer
and Development, National Institutes of Health.
[FR Doc. 2016-26390 Filed 11-1-16; 8:45 am]
BILLING CODE 4140-01-P
